LEVERAGE LONG - MODERNA | Market Closed - BME 11:30:00 2024-04-26 EDT | ||
| 1.46 EUR | +5.04% |
|
| Current month | -1.35% | ||
| 1 month | -6.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.46 | +5.04% | 0 |
| 24-04-25 | 1.39 | -6.08% | 0 |
| 24-04-24 | 1.48 | 0.00% | 0 |
| 24-04-23 | 1.48 | +8.82% | 0 |
| 24-04-22 | 1.36 | 0.00% | 0 |
Delayed Quote BME
Last update April 26, 2024 at 11:30 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| Z0973 | |
| ISIN | DE000SN2BJE9 |
| Date issued | 2021-05-27 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 4.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.1 € |
|---|---|
| Lowest since issue | 0.72 € |
| Spread | 0.01 € |
| Spread % | 0.68% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
108
USD
Average target price
134.3
USD
Spread / Average Target
+24.39%
- Stock Market
- Certificates
- Z0973 Certificat
